Consano Medical, a San Francisco, CA-based medical device company, closed a $3.9m Series A funding.
A group of clinical physicians, hospital administrators, and medical device development consultants organized by Ehrenberg Chesler Capital Partners San Antonio led the round.
Led by Dan Burnett, M.D., CEO, Consano Medical focuses on the development of an intelligent monitoring device for detecting and managing sepsis in patients in intensive care units. A spin out of the medical device incubator TheraNova, the company has received two NIH grants for further device development, pre-clinical testing and clinical testing
It now intends to use the funding to continue the clinical development of its OmniSense® monitoring devices, which utilizes the urinary drainage catheter found in all ICU patients to extract valuable clinical data to provide earlier diagnosis of Sepsis or Systemic Inflammatory Response Syndrome (SIRS) and optimize its treatment by detecting and preventing fluid overload during fluid resuscitation.